GLX-7013159(GLX-7013159) - 药物靶点：NOX4_在研适应症：糖尿病_专利_临床

概要

基本信息

药物类型

化学药

别名

靶点

NOX4

作用方式

抑制剂

作用机制

NOX4抑制剂(NADPH氧化酶-4抑制剂)

治疗领域

内分泌与代谢疾病

在研适应症

糖尿病

非在研适应症-

原研机构

Glucox Biotech AB

在研机构

Glucox Biotech AB

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 GLX-7013159 相关的临床结果

登录后查看更多信息

100 项与 GLX-7013159 相关的转化医学

登录后查看更多信息

100 项与 GLX-7013159 相关的专利（医药）

登录后查看更多信息

1

项与 GLX-7013159 相关的文献（医药）

Free Radical Research

The selective NOX4 inhibitor GLX7013159 decreases blood glucose concentrations and human beta-cell apoptotic rates in diabetic NMRI nu/nu mice transplanted with human islets

Article

作者: Wikström, Per ; Welsh, Nils ; Elksnis, Andris ; Lau, Joey ; Carlsson, Per-Ola

NADPH oxidase 4 (NOX4) inhibition has been reported to mitigate diabetes-induced beta-cell dysfunction and improve survival in vitro, as well as counteract high-fat diet-induced glucose intolerance in mice. We investigated the antidiabetic effects of the selective NOX4 inhibitor GLX7013159 in vivo in athymic diabetic mice transplanted with human islets over a period of 4 weeks. The GLX7013159-treated mice achieved lower blood glucose and water consumption throughout the treatment period. Furthermore, GLX7013159 treatment resulted in improved insulin and c-peptide levels, better insulin secretion capacity, as well as in greatly reduced apoptotic rates of the insulin-positive human cells, measured as colocalization of insulin and cleaved caspase-3. We conclude that the antidiabetic effects of NOX4 inhibition by GLX7013159 are observed also during a prolonged study period in vivo and are likely to be due to an improved survival and function of the human beta-cells.

100 项与 GLX-7013159 相关的药物交易

登录后查看更多信息